Pendetide

Summary

Pendetide, also known as capromab pendetide or ProstaScint, is an FDA‑approved radiopharmaceutical used for diagnostic imaging of prostate cancer. The agent consists of a murine monoclonal antibody (7E11‑C5.3) linked to the chelator GYK‑DTPA and labeled with indium‑111. After intravenous injection, it enables single‑photon emission computed tomography (SPECT) to visualize prostate‑specific membrane antigen (PSMA)–expressing tissue, primarily to assess the extent of primary or metastatic disease.

Mechanism of Action

The antibody component of pendetide binds the intracellular domain of PSMA, a type II transmembrane glycoprotein overexpressed on prostate cancer cells and in tumor neovasculature. Because the epitope is intracellular, the antibody can only bind cells with compromised membranes (necrotic or dying tissue). The attached DTPA chelator holds indium‑111, a gamma‑emitting radionuclide, allowing external detection of bound antibody by SPECT imaging.

What the Research Shows

Clinical evaluations reported variable sensitivities (≈49‑77%) and specificities (≈35‑96%) for detecting lymph‑node metastases or recurrent disease, with higher specificity in some studies. A 1998 review highlighted improved detection over non‑invasive techniques when used alongside other imaging modalities. However, the intracellular target limits tumor penetration and yields lower signal‑to‑noise ratios compared with antibodies directed at extracellular PSMA epitopes. Newer small‑molecule PSMA ligands and extracellular‑domain antibodies are under investigation for better performance. The FDA approved indium‑111‑capromab pendetide in 1996, and it remains the only antibody‑based PSMA imaging agent with regulatory clearance.

Reported Benefits

Pendetide offers a clinically validated method to image PSMA‑expressing prostate cancer, providing whole‑body assessment of primary, nodal, and metastatic lesions. Its high specificity in certain cohorts (up to 96%) can aid surgical planning and guide management when combined with conventional imaging. As an FDA‑approved product, it is available in hospitals with nuclear medicine capabilities.

Limitations of the Evidence

Binding to the intracellular PSMA domain restricts uptake to necrotic tissue, resulting in modest sensitivity and occasional false‑negative scans. Variable performance across studies, limited tumor penetration, and competition from newer extracellular‑targeting antibodies and small‑molecule PSMA ligands reduce its current clinical appeal. Immunogenicity (human anti‑mouse antibodies) can limit repeat use. Kidney and liver accumulation of radiolabel may affect image quality.

Safety Considerations

Adverse events were reported in about 4% of patients, most commonly mild elevations in bilirubin, hypertension, hypotension, liver enzymes, or injection‑site reactions. Human anti‑mouse antibodies developed in 8% after a single dose and up to 19% after repeated administrations, potentially affecting subsequent imaging or causing hypersensitivity. Overall, the agent is well tolerated, but clinicians monitor hepatic function and blood pressure post‑injection.

How It Is Administered

Pendetide is administered as a single intravenous infusion of indium‑111‑labeled antibody. After injection, imaging is typically performed 24–72 hours later using SPECT or SPECT/CT to capture gamma emissions from indium‑111. The formulation is supplied as a sterile radiopharmaceutical prepared under nuclear pharmacy conditions.

Routes of Administration

Goals & Uses

• Monitoring biochemical recurrenceOncology / SurveillanceLow
• Detection of prostate cancer metastasesDiagnostic ImagingModerate
• Staging of prostate cancerOncology / StagingModerate

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
• Hypersensitivity to murine antibodiesImmunologicHigh

Adverse Effects

• Radiation exposureRadiologicalCommon
• Hypersensitivity / allergic reactionsImmunologicUncommon
• Injection site reactionsLocalUncommon
• HAMA developmentImmunologicUncommon

Drug Interactions

• ImmunosuppressantsLowPotential interaction with immune pathways or infection risk
• Other radiopharmaceuticalsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Prior murine antibody exposureImmunologic HistoryRelative
• Patients with renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionUnknownLimited regulatory approval history in Europe; largely superseded by PSMA PET imaging agents
• United StatesWithdrawnApproved: Detection of intra-pelvic metastases and recurrent prostate cancer (PSMA imaging)FDA-approved in 1996 as capromab pendetide (ProstaScint); voluntarily withdrawn from market circa 2017–2018 for commercial reasons, not due to safety issues

Capromab pendetide (ProstaScint) was FDA-approved in 1996 for imaging of prostate cancer. The product was withdrawn from the US market by Aytu BioScience around 2017–2018 for commercial reasons, not safety concerns.

Evidence & Sources

• (123)I-Labeled (S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedoic acid
  Journal ArticleModerateChopra A2004-01-01T00:00:00.000000Z
• N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-S-[(11)C]methyl-L-cysteine
  Journal ArticleModerateChopra A2004-01-01T00:00:00.000000Z
• N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[(18)F]fluorobenzyl-L-cysteine
  Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
• Cy7-(3S,7S)-26-Amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid
  Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
• Capromab pendetide. A review of its use as an imaging agent in prostate cancer
  Journal ArticleModerateLamb HM, Faulds D1998-01-01T00:00:00.000000Z
• (111)In-Capromab pendetide
  Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z

Frequently Asked Questions